Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Ryerson LZ, Foley J, Chang I, Kister I, et al. Neurology 2019;93:e1452-e1462.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ryerson LZ, Foley J, Chang I, Kister I, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology 2019;93:e1452-e1462.
PMID: 31515290